期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 55, 期 2, 页码 602-606出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201508716
关键词
cancer; inhibitors; p300; protein-protein interactions; Skp2
资金
- National Science Foundation [NSF CHE-1212720]
- United States Department of Defense [W81XWH-10-PCRP-EHDA]
- National Research Foundation of Korea [NRF-2014M3A9D9069711]
- National Research Foundation of Korea [2014M3A9D9069711] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Skp2 is thought to have two critical roles in tumorigenesis. As part of the SCFSkp2 ubiquitin ligase, Skp2 drives the cell cycle by mediating the degradation of cell cycle proteins. Besides the proteolytic activity, Skp2 also blocks p53-mediated apoptosis by outcompeting p53 for binding p300. Herein, we exploit the Skp2/p300 interaction as a new target for Skp2 inhibition. An affinity-based high-throughput screen of a combinatorial cyclic peptoid library identified an inhibitor that binds to Skp2 and interferes with the Skp2/p300 interaction. We show that antagonism of the Skp2/p300 interaction by the inhibitor leads to p300-mediated p53 acetylation, resulting in p53-mediated apoptosis in cancer cells, without affecting Skp2 proteolytic activity. Our results suggest that inhibition of the Skp2/p300 interaction has a great potential as a new anticancer strategy, and our Skp2 inhibitor can be developed as a chemical probe to delineate Skp2 non-proteolytic function in tumorigenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据